Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D, Bach C, Böttcher M, Beier F, Röhner L, Stoll A, Rehli M, Gebhard C, Lischer C, Eberhardt M, Vera J, Büttner-Herold M, Bitterer K, Balzer H, Leffler M, Jitschin S, Hundemer M, Awwad MHS, Busch M, Stenger S, Völkl S, Schütz C, Krönke J, Mackensen A, Bruns H. Mougiakakos D, et al. Among authors: kronke j. Cancer Immunol Res. 2021 Mar;9(3):265-278. doi: 10.1158/2326-6066.CIR-20-0555. Epub 2021 Feb 9. Cancer Immunol Res. 2021. PMID: 33563611
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl SR, Schmalbrock LK, Bauhuf I, Meyer T, Dolnik A, Szyska M, Blätte TJ, Knödler S, Röhner L, Miller D, Kull M, Langer C, Döhner H, Letai A, Damm F, Heckl D, Bullinger L, Krönke J. Bohl SR, et al. Among authors: kronke j. Blood Adv. 2021 May 11;5(9):2391-2402. doi: 10.1182/bloodadvances.2020003541. Blood Adv. 2021. PMID: 33950175 Free PMC article.
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S, Langer C. Krönke J, et al. Leukemia. 2017 Jun;31(6):1363-1367. doi: 10.1038/leu.2016.384. Epub 2016 Dec 26. Leukemia. 2017. PMID: 28017969 Clinical Trial.
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, Müller S, Popp O, Kull M, Haji M, Gütschow M, Döhner H, Walther W, Keller U, Bullinger L, Mertins P, Krönke J. Ng YLD, et al. Among authors: kronke j. Nat Commun. 2022 Feb 23;13(1):1009. doi: 10.1038/s41467-022-28515-1. Nat Commun. 2022. PMID: 35197447 Free PMC article.
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Krönke J, et al. Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29. Science. 2014. PMID: 24292625 Free PMC article.
Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C, Lindner S, Udeshi ND, Mani DC, Kehm H, Köpff S, Carr SA, Gütschow M, Krönke J. Steinebach C, et al. Among authors: kronke j. ACS Chem Biol. 2018 Sep 21;13(9):2771-2782. doi: 10.1021/acschembio.8b00693. Epub 2018 Sep 5. ACS Chem Biol. 2018. PMID: 30118587
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, Munzert G, Einsele H. Topp MS, et al. Among authors: kronke j. J Clin Oncol. 2020 Mar 10;38(8):775-783. doi: 10.1200/JCO.19.02657. Epub 2020 Jan 2. J Clin Oncol. 2020. PMID: 31895611 Clinical Trial.
58 results